Compare COHN & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COHN | BTMD |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 46.2M |
| IPO Year | 2003 | 2021 |
| Metric | COHN | BTMD |
|---|---|---|
| Price | $11.10 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.83 |
| AVG Volume (30 Days) | 14.2K | ★ 365.7K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | ★ 5537.50 | 722.22 |
| EPS | ★ 1.36 | N/A |
| Revenue | ★ $275,564,000.00 | $192,219,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | N/A | $6.58 |
| P/E Ratio | $8.10 | ★ N/A |
| Revenue Growth | ★ 246.19 | N/A |
| 52 Week Low | $9.19 | $1.27 |
| 52 Week High | $32.60 | $3.58 |
| Indicator | COHN | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 42.93 | 49.37 |
| Support Level | $11.15 | $1.63 |
| Resistance Level | $11.81 | $2.17 |
| Average True Range (ATR) | 0.42 | 0.13 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 19.11 | 80.00 |
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.